Sent by email October 19, 2017 to the following New Hampshire Senators and Representatives:

Sen. John Reagan, Chairman (R-Deerfield) john.reagan111@gmail.com
Sen. Kevin Avard (R-Nashua) Kevin.Avard@leg.state.nh.us
Sen. Dan Feltes (D-Concord) Dan.Feltes@leg.state.nh.us
Sen. Harold French (R-Franklin) Harold.French@leg.state.nh.us
Sen. Jay Kahn (D-Keene) Jay.Kahn@leg.state.nh.us
Sen. Martha Fuller Clark (Alt.) (D-Portsmouth) Martha.FullerClark@leg.state.nh.us
Sen. Lou D'Allesandro (Alt.) (D-Manchester) dalas@leg.state.nh.us
Sen. William Gannon (Alt.) R-Sandown (aide's email) katherine.bourque@leg.state.nh.us
Sen. Dan Innis (Alt.) (R-New Castle) daninnis@mac.com
Rep. Carol M. McGuire, Vice Chair (R-Epsom) carol@mcguire4house.com
Rep. John Graham (R-Bedford) graham4rep@hotmail.com
Rep. William A. Hatch (D-Gorham) William.Hatch@leg.state.nh.us
Rep. Rick M. Ladd (R-Haverhill) ladd.nhhouse@charter.net
Rep. Peter B. Schmidt (D-Dover) peterbarrettschmidt@gmail.com
Rep. Karen Ebel (Alt.) (D-New London) Karen.Ebel@leg.state.nh.us
Rep. Suzanne H. Gottling (Alt.) (D-Sunapee) sgottling@comcast.net
Rep. Carolyn Mathews (Alt.) (R-Raymond) Carolyn.Matthews@leg.state.nh.us
Rep. Bill Ohm (Alt.) (R-Nashua) billohm2010@aol.com
Rep. John Sytek (Alt.) (R-Salem) john.sytek@leg.state.nh.us

Dear Senator / Representative,

On behalf of the New Hampshire Lupron victims who have contacted me, after hearing yesterday afternoon on the radio that the Joint Legislative Committee on Administrative Rules will meet tomorrow to address the proposed rule by New Hampshire's Department of Health and Human Services to make "gender reassignment" a covered service for minors and adults, I was compelled to write.

Lupron, the most frequently prescribed 'puberty blocker', is not FDA approved for use in the transgender population. Lupron is FDA approved for pediatric use for the indication of "precocious puberty", and also is FDA approved in women for the indications of 'endometriosis' and 'anemia associated with fibroids when iron therapy alone is ineffective', as well as being FDA approved in men for the indication of prostate cancer.

As founder of 'Lupron Victims Hub' (www.LupronVictimsHub.com), I have been contacted by many men, women, and children who report serious adverse events on and following discontinuation of Lupron, and are seeking medical and legal assistance. The effects of Lupron in children (as well as full effects in adults) remain unknown. No rule should be proposed without full disclosure of Lupron's known risks (see: http://lupronvictimshub.com/risks.html), and no rule should be proposed without written plans for assistance and compensation in the event of iatrogenic injury.

Because of my website I have heard from (among others) many mothers of Lupron-treated children (for precocious puberty) as well as hearing from the now-adult treated children (for precocious puberty). Please see my recent 6-part series on the risks of pediatric use of Lupron (including transgender use), and specifically see excerpts of these emails (in 'Part 1 – Lupron & Precocious Puberty: Parents and Patients Speak Out' -http://lupronvictimshub.com/media.html). The very serious adverse events reported and the desperate pleas for help are alarming and heart-wrenching. Please read these haunting excerpts ... are similar complaints to be sent to DHHS from the transgender population after their 'treatment' with Lupron (or other GnRHas) has taken its toll?

As recited in my 6-part series and as reported in a February 2017 Kaiser Report, the FDA was "currently conducting a specific review of nervous system and psychiatric events in association with the use of GnRH agonists, [a class of drugs] including Lupron, in pediatric patients," ... The FDA is also reviewing deadly seizures stemming from the pediatric use of Lupron and other drugs in its class. While there are other drugs similar to Lupron, it is a market leader and thousands of women have joined Facebook groups or internet forums in recent years claiming that Lupron ruined their lives or left them crippled. But the FDA has yet to issue additional warnings about pediatric use, and unapproved uses of the drugs persist. ... " (https://khn.org/news/women-fear-drug-they-used-to-halt-puberty-led-to-health-problems/).

Moreover, the NIH awarded $5.7 million for a 5-year multi-center study in 2015, "the first in the US to evaluate the long-term outcomes of medical treatment for transgender youth", seeking data on the "physiological and psychosocial impact, as well as safety, of hormone blockers". For further info, see: https://www.hormonesmatter.com/lupron-reproductive-injury/ .

Without data on the safety of Lupron in the transgender population, coupled with Lupron's known risks, facilitating further use of this drug should, in my opinion, be criminal. History speaks volumes as to how horribly Lupron victims fare – the tragedies within the emails I receive are replicated EVERYWHERE on the internet (i.e., see petitions, reviews, stories, comments, etc. - http://lupronvictimshub.com/links.html), yet despite their numbers and alarming experiences remain a marginalized group, too ill and financially devastated to effectively mobilize.

Government agencies should be doing all they can to help the victims of this drug (men, women, and children) and they should be removing Lupron from the market to prevent further victims from accumulating. The New Hampshire government should not be attempting to increase Lupron's use and add to the number of casualties. Untold numbers of lives and careers have been ruined from a wide range of adverse physical and psychological events. More than a thousand deaths have been reported, numerous suicides have occurred, and a homicide has been reported to the FDA.

The New Hampshire residents who have contacted me seeking help have reported various health problems, including bone pain, abdominal issues, memory problems,

seizures, and a brain tumor. For an example of a New Hampshire resident's experience with Lupron 'treatment', see signatory dated Sept. 22, 2016 on a Petition2Congress requesting an investigation into Lupron's adverse effects
- http://www.petition2congress.com/ctas/investigation-lupron-side-effects-leuprolide-acetate .

There are other New Hampshire signatories on this petition, which to date claims that 10,772 messages have been sent to Representatives and Senators on Capitol Hill. It is possible you have already received messages from constituents reporting adverse effects from Lupron, seeking your help. If so, what was your response to these constituents' plea for help?

What would be your response to the transgenders' complaints of Lupron injury?

Hopefully, now that you have been informed of Lupron's effects and Lupron's risks, you will endeavor to see that no other individual – transgender or non-transgender – is exposed to this toxin.

Should you have any questions, please do not hesitate to contact me.

Respectfully submitted,

Lynne Millican, RN, BSN, paralegal (disabled post-Lupron)

West Roxbury, MA.
617-327-9182
www.LupronVictimsHub.com
lynnemill@aol.com